VC-backed Delphinus hires finance VP

Delphinus Medical Technologies, which is backed by Arboretum Ventures and Beringea, has appointed Shawn O’Brien as vice president of finance. Previously, O’Brien worked at CytoPherx. Delphinus is a maker of SoftVue, a whole breast ultrasound system.


PLYMOUTH TOWNSHIP, Mich. – November 5, 2014 – Delphinus Medical Technologies, Inc., announced today that Shawn O’Brien has been named Vice President of Finance, expanding further the recent appointments to the executive leadership team. He joins the company at a formative time with the advancement of SoftVue™, a true innovation in 3D whole breast ultrasound technology.

O’Brien comes to Delphinus having a successful career as a financial professional with extensive experience across a variety of corporate functions, most recently at CytoPherx of Ann Arbor, MI. In addition to spear-heading all aspects of fiscal operations, he was responsible for leading the project management team, including clinical trial guidance, and administering vendor relations. With his direction, the company realized sizable proceeds from on-time and under-budget project completions, based on targeted revenue-sparing strategies and focused implementation. While at Kux Architectural Products of Canton, Mich., O’Brien was promoted to head of finance, advancing through successively responsible positions at the company. He began his professional career as Controller at Advanced Material Process Corporation of Wayne, Mich.

“We are very pleased that Shawn has joined our team,” said Mark J. Forchette, president and chief executive officer of Delphinus. “We are entering an important growth phase, and his appointment is key as we develop a strong foundation to accelerate our strategies. Shawn’s contribution, based on his successful track record of knowledge and experience, will be critical as we move forward in our commitment to bring transformative advances in breast cancer screening with our SoftVue technology.”

O’Brien received his baccalaureate degree in accounting from University of Michigan, Flint, Mich. In addition, he earned a Masters of Business Administration at the same institution.

Delphinus has developed SoftVue, featuring a sophisticated imaging capability not possible with any other ultrasound system. Powered with circular, volumetric transducer technology, SoftVue images the entire breast in a continuous 360° scan sequence, moving from the back of the breast to the front, creating a cross-sectional image map. The procedure is streamlined, averaging two minutes per breast, and captures not only reflected echoes but the signals transmitted through the tissue. SoftVue provides a consistent and uniform exam without reliance on operator skill and technique, promoted by its automated, reproducible workflow and efficiency.

About Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. is a pioneering medical imaging company that has developed SoftVue™, the first circular array transducer technology that has received U.S. Food and Drug Administration clearance. The patented technology is a whole breast ultrasound tomography imaging device that delivers no radiation, requires no compression, and images the entire breast with a single scan. SoftVue is indicated for use as a B-mode ultrasonic imaging system and is not intended to be used as a replacement for screening mammography. Delphinus is capitalized through principal investments by Arboretum Ventures, Ann Arbor, Mich., Beringea, Farmington Hills, Mich., and North Coast Technology Investors, Ann Arbor, Mich. For more information, visit